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proteins controls ErbB signaling downstream to the
MAPK pathway, and transcription of the respective
genes is simultaneously upregulated by the ligand-acti-
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1Department of Biological Regulation vated ErbB orthologs of worms and insects [2]. A proto-
typical regulator is the C. elegans protein SLI-1, whose2 Department of Neurobiology
The Weizmann Institute of Science human ortholog, c-Cbl, binds to EGF-activated recep-
tors, thereby enabling ubiquitination and subsequentRehovot 76100
Israel endocytosis of EGFRs [3, 4]. The mechanism of another
regulator, Sprouty, is less understood. Drosophila
Sprouty (dSpry) was originally identified as an antago-
nist of the Breathless fibroblasts growth factor (FGF)Summary
receptor during tracheal development [5]. Additional
studies demonstrated that dSpry can also inhibit theBackground: Growth factors and their receptor tyrosine
Drosophila EGFR (DER), as well as other receptors [5–7].kinases play pivotal roles in development, normal physi-
Although dSpry has been shown to impede MAPK acti-ology, and pathology. Signal transduction is regulated
vation by DER, different mechanisms were proposed,primarily by receptor endocytosis and degradation in
including inhibition at the level of Drk/Grb2, the Raslysosomes (“receptor downregulation”). c-Cbl is an
GTPase-activating protein [6], or the D-Raf kinase [7].adaptor that modulates this process by recruiting bind-
Four mammalian sprouty genes have been identifieding partners, such as ubiquitin-conjugating enzymes.
based on their sequence similarity to dSpry. MammalianThe role of another group of adaptors, Sprouty proteins,
Sprouty proteins share a well-conserved, carboxyl-ter-is less understood; although, studies in insects impli-
minal, cysteine-rich domain, which is required for induc-cated the founder protein in the negative regulation of
ible translocation of Sprouty proteins to the plasmaseveral receptor tyrosine kinases.
membrane [8, 9], and a less conserved N terminus. LikeResults: By utilizing transfection of living cells, as well
their insect ortholog, mammalian Sprouty proteins in-as reconstituted in vitro systems, we identified a dual
hibit terminal branching in the lung, as well as FGF-regulatory mechanism that combines human Sprouty2
mediated limb development and bone outgrowth [10–and c-Cbl. Upon activation of the receptor for the epider-
12]. In vitro, Sprouty proteins inhibit FGF-induced differ-mal growth factor (EGFR), Sprouty2 undergoes phos-
entiation of HUVEC and PC12 cells, as well as EGF- andphorylation at a conserved tyrosine that recruits the Src
FGF-induced migration of HeLa cells [8, 13, 14]. It ishomology 2 domain of c-Cbl. Subsequently, the flanking
interesting, however, that the inhibitory effect of SproutyRING finger of c-Cbl mediates poly-ubiquitination of
proteins differs when tested with distinct growth factors.Sprouty2, which is followed by proteasomal degrada-
Thus, although EGF and FGF upregulated the expres-tion. Because phosphorylated Sprouty2 sequesters ac-
sion of Spry2 and Spry4 in HEK-293 cells, forced expres-tive c-Cbl molecules, it impedes receptor ubiquitination,
sion of each protein inhibited FGF-, but not EGF-, in-downregulation, and degradation in lysosomes. This
duced MAPK activation [15]. Similarly, when tested oncompetitive interplay occurs in endosomes, and it regu-
endothelial cells, Spry2 and Spry4 inhibited mitogenesislates the amplitude and longevity of intracellular signals.
induced by FGF, vascular endothelial growth factorConclusions: Sprouty2 emerges as an inducible antag-
(VEGF), and EGF, but only FGF- and VEGF-inducedonist of c-Cbl, and together they set a time window
MAPK activation was inhibited in these cells [8]. Further-for receptor activation. When incorporated in signaling
more, mutagenesis of a conserved tyrosine of Spry2networks, the coupling of positive (Sprouty) to negative
(tyrosine 55) conferred dominant-negative activities with(Cbl) feedback loops can greatly enhance output diversi-
respect to inhibition of FGF signaling while sparing EGFfication.
signaling [15]. Hence, it is plausible that mammalian
Sprouty proteins regulate the EGFR and FGFR pathways
Introduction through distinct mechanisms.
Currently, the mechanism underlying distinct actions
Receptor tyrosine kinases (RTKs) are primary mediators of Sprouty proteins in different signaling pathways is
of extracellular signals regulating cell growth, differenti- incompletely understood. It is clear that Sprouty iso-
ation, and migration. An example is provided by the ErbB forms specifically inhibit the MAPK pathway, but other
family of receptors: while fine-tuning of ErbB signaling pathways, such as the phosphtidylinositol 3 kinase, are
through the mitogen-activated kinases (MAPKs) and not affected. MAPK modulation by mammalian Sproutys
other pathways is essential for normal embryonic devel- has variably been attributed to prevention of Ras activa-
opment, deregulated signaling promotes malignancies tion [13] and to interference at the level of Raf [16].
in adulthood (reviewed in [1]). Invertebrates proved to Recent reports have raised yet another interesting pos-
be a rich source of lessons relevant to the regulation sibility. Accordingly, Spry2 binds to the RING finger of
of ErbB signaling in mammals. A group of regulatory c-Cbl, thereby inhibiting recruitment of a ubiquitin-
loaded E2 enzyme [17, 18] and delaying ubiquitination
and endocytosis of EGFR [17, 19]. Because c-Cbl nega-*Correspondence: yosef.yarden@weizmann.ac.il
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Figure 1. Following Stimulation with EGF, Spry2 Is Phosphorylated on Tyrosine 55 and Partially Colocalizes with the Internalized EGFR
(A) The alignment presents the Cbl binding sites of Zap-70, EGFR, and the C. elegans receptor for EGF (Let-23), along with a related motif of
Sprouty proteins. Asterisks mark conserved residues.
(B–D) HEK-293 cells coexpressing HA-Spry2, or HA-Spry2-Y55F, and EGFR proteins, either wild-type (WT, [B] and [D]) or a kinase-defective
mutant (KD; K721A), were incubated for 10 min without or with EGF (100 ng/ml) and cell extracts subjected to immunoprecipitation (IP) and
immunoblotting (IB) with the indicated antibodies.
(E) CHO cells coexpressing EGFR and HA-Spry2, either wild-type or Y55F, were incubated for 10 min at 37C without or with EGF (100 ng/ml),
fixed, permeabilized, and incubated with anti-HA and anti-EGFR antibodies. Thereafter, cells were incubated with Cy2- and Cy3-congugated
secondary antibodies. The right column presents the overlay of EGFR fluorescence (red) and Spry2 fluorescence (green), generating a yellow
color in the areas of colocalization.
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tively regulates several RTKs but is uncoupled to other the Y55F mutant was identical to that of wild-type Spry2
(Figure 1E), indicating that phosphorylation at tyrosinereceptors like ErbB-3, this mechanism may explain how
Sprouty isoforms differentially regulate signaling by 55 is not required for Spry2 localization. Similar to these
results, Spry2 was localized to the plasma membrane,specific RTKs. The present study is aimed at Spry2-
Cbl-EGFR interactions. Here, we show that Spry2 is vesicular structures, and perinuclear regions of HUVEC
cells [8], and, although it has been previously shownphosphorylated on tyrosine 55 in response to EGF stim-
ulation, and that phosphorylated Spry2 associates with that Spry2 translocates to membrane ruffles upon stimu-
lation by growth factors [8, 9], the extent of this phenom-c-Cbl and undergoes poly-ubiquitination. Furthermore,
Spry2 and EGFR competitively bind to the SH2 domain enon was limited in our cellular system. Taken together,
the results presented in Figure 1 indicate that activationof c-Cbl. This novel configuration allows coupling of a
negative regulatory loop to a reversible positive feed- of EGFR promotes phosphorylation of Spry2 on tyrosine
55, but this modification is not necessary for colocaliza-back loop, and together they fine-tune EGF signaling.
tion of Spry2 and EGFR to endosomes.
Results
c-Cbl Is Recruited to Spry2 upon EGF-Induced
Phosphorylation at Tyrosine 55Spry2 Undergoes EGF-Induced Phosphorylation
at Tyrosine 55 and Partly Colocalizes To test the prediction that tyrosine 55 functions as an
inducible docking site for c-Cbl, we expressed in HEK-with the Internalized EGFR
Because modification of tyrosine 55 of Spry2 trans- 293 cells both c-Cbl and a peptide-tagged Spry2, along
with EGFR, and probed c-Cbl’s immunoprecipitates withformed the negative modulator into an enhancer of the
MAPK pathway [15], we reasoned that the correspond- antibodies to the tagged Spry2. Although Spry2 was
detectable in c-Cbl’s immunoprecipitates isolated froming site might be involved in signaling regulation. Exami-
nation of the relevant amino acid sequence revealed that unstimulated cells, preexposure of cells to EGF in-
creased the physical association between Spry2 andtyrosine 55 is embedded in a short motif that conforms to
two consensus phosphotyrosine- (pY) containing dock- c-Cbl (Figure 2A). In contrast to wild-type Spry2, mutants
in which tyrosine 55 has been replaced with either aning sites for c-Cbl (see Figure 1A). The sequence down-
stream to tyrosine 55 conforms to the motif pYXXXP alanine or a phenylalanine displayed neither basal nor
inducible complex formation. Consistent with the possi-that we previously identified as c-Cbl’s docking site in
EGFR [3], and the upstream motif (D/N)XpY has pre- bility that phosphorylated tyrosine 55 and the sur-
rounding amino acids constitute a binding site for c-Cbl,viously been identified as c-Cbl’s binding site in Zap-
70 [20]. To test the prediction that tyrosine 55 is inducibly substitution of the well-conserved proline at position3
significantly reduced the physical association of the cor-phosphorylated, we coexpressed in HEK-293 cells
EGFR and a peptide-tagged Spry2. Short exposure of responding mutant with c-Cbl, but mutagenesis of the
adjacent, nonconserved glycine residue (mutant de-transfected cells to EGF, followed by immunoprecipita-
tion of Spry2, revealed that EGF enhanced tyrosine noted G58A) did not affect Cbl-Spry2 interactions (data
not shown).phosphorylation of Spry2 (Figure 1B; note that Spry2
appears as a diffuse doublet band in gels, and the over- We next attempted to detect the interaction of Spry2
with the endogenous c-Cbl of CHO cells. In this cellularexpressed EGFR displays basal autophosphorylation).
Interestingly, we detected coimmunoprecipitation of environment, the endogenous c-Cbl was undetectable
in Spry2 immunoprecipitates (Figure 2B), but introduc-phosphorylated EGFR with Spry2 by using anti-phos-
photyrosine antibodies (Figure 1B), but the extent of tion of EGFR and treatment with EGF led to phosphoryla-
tion of both Spry2 and c-Cbl, and the latter physicallythis interaction appeared very weak when tested with
antibodies to EGFR (data not shown). An indication that associated with Spry2. Although these results predict
that EGFR phosphorylates Spry2, our attempts to cap-the intrinsic kinase activity of EGFR was responsible for
Spry2 phosphorylation, as well as for partial degrada- ture the putative complex have failed. Consistent with
indirect interactions, coexpression of wild-type (WT) andtion, was provided by an experiment that used a kinase-
dead mutant of EGFR (K721A; Figure 1C). Mutagenesis of Y55F-Spry2 reduced phosphorylation of the wild-type
form (Figure 2C), probably due to competitive bindingSpry2’s tyrosine 55 completely abolished EGF-induced
phosphorylation (Figure 1D), implying that this residue to an adaptor protein. These results are consistent with
the following scenario: upon binding of EGF, the kinaseis an exclusive site for modification by EGF.
To gain insights into Spry2-EGFR interactions, we ex- domain of EGFR phosphorylates tyrosine 55 of Spry2,
and this site recruits c-Cbl. This sequence of eventsamined their possible colocalization in Chinese hamster
ovary cells (CHO), which, unlike HEK-293 cells, lack en- was supported by in vitro experiments. First, an immu-
noprecipitated EGFR enhanced phosphorylation of adogenous EGFRs. Immunofluorescence and confocal
microscopy confirmed EGF-induced translocation of recombinant wild-type Spry2 (in the form of a glutathi-
one-S-transferase [GST]-Spry2 fusion protein), but theEGFR to endocytotic vesicles (Figure 1E). In unstimu-
lated cells, Spry2 and EGFR partly colocalized at the corresponding Y55F mutant underwent no phosphoryla-
tion (Figure 2D). Second, c-Cbl derived from overex-plasma membrane, but Spry2-containing cytoplasmic
vesicles were largely devoid of EGFR. However, upon pressing HEK-293 cells specifically bound the phos-
phorylated form of Spry2 (Figure 2E); no association wasexposure to EGF, a significant fraction of EGFR mole-
cules translocated to these Spry2-containing vesicles, observed when the nonphosphorylatable Y55F-Spry2
was tested, or when phosphorylation of wild-type Spry2thereby identifying them as endosomes. Localization of
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Figure 2. Tyrosine 55 of Spry2 Enables Formation of Spry-Cbl Complexes
(A) HEK-293 cells coexpressing EGFR, HA-Cbl, and the indicated HA-Spry2 proteins were incubated for 10 min without or with EGF (100 ng/
ml), and c-Cbl immunopreciptates were analyzed.
(B) CHO cells coexpressing EGFR and HA-Spry2 were incubated for 10 min at 37C without or with EGF (100 ng/ml). Cell extracts were
analyzed either directly or following Spry2 immunoprecipitation, and the endogenous c-Cbl was detected by using specific antibodies. IgH
denotes the antibody heavy chain.
(C) CHO cells were transfected with EGFR and HA-Spry2 expression vectors, along with increasing amounts of a plasmid encoding the Y55F-
Spry2 mutant. A total of 48 hr after transfection, the cells were incubated with EGF for 10 min. Subsequently, cell extracts were analyzed with
the indicated antibodies.
(D) Immunoprecipitates of EGFR derived from A431 cells were incubated at 30C for 30 min with the indicated GST-Spry2 proteins (200 ng
each, see a stained gel in the upper panel), MnCl2 (10 mM), and [32P]ATP. Subsequently, supernatants were analyzed by pull-down (PD) with
gluthatione beads and autoradiography.
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was inhibited by a specific inhibitor of EGFR’s kinase tion precedes degradation of associated phospho-
Spry2 molecules. As expected, maximal poly-ubiquiti-activity (AG1478).
To form physical complexes, Spry2 and c-Cbl must nation of Spry2 required stimulation with EGF, and it
was promoted by surprisingly low overexpression ofjuxtapose within cells. Confocal microscopy performed
on transiently transfected CHO cells revealed that the c-Cbl (Figure 3C). Significantly lower levels of the char-
acteristic smear of ubiquitinated Spry2 species weretwo proteins display partly overlapping patterns of distri-
bution in resting cells (Figure 2F). Shortly after exposure observed in the absence of an overexpressed c-Cbl, or
when cells expressing the Y55F mutant were analyzed.to EGF, c-Cbl translocated to Spry2-containing struc-
tures, resembling endosomes loaded with internalized Likewise, a mutant of c-Cbl that cannot bind Spry2,
namely, G306E-Cbl, was unable to increase poly-ubiqui-EGFR molecules (see Figure 1E and [21, 22]). Interest-
ingly, the nonphosphorylatable Y55F-Spry2 mutant also tination of Spry2 (data not shown). Hence, these results
suggest that c-Cbl acts as an inducible E3 ubiquitincolocalized with c-Cbl in EGF-stimulated cells, sug-
gesting that c-Cbl and Spry2 are destined to the same ligase of Spry2; we verified this possibility by using a
cell-free system. In addition to recombinant GST-Spry2,vesicular structures independent of their mutual associ-
ation. In conclusion, ligand-induced activation of the or the Y55F mutant, the in vitro test system included an
immunopurified EGFR, a radiolabled ubiquitin, E1, E2EGFR leads to Spry2 phosphorylation and to the translo-
cation of c-Cbl to Spry2-containing vesicles. Subse- (UbcH5C), and c-Cbl as an E3 ligase. Consistent with
the data from living cells, c-Cbl ubiquitinated wild-typequently, phosphorylated Spry2 found in close proximity
to c-Cbl allows for the formation of Spry2-Cbl physical GST-Spry2, but not the GST-Y55F mutant (Figure 3D),
and a specific tyrosine kinase inhibitor (AG1478) abol-complexes.
ished modification of Spry2 (data not shown).
Next, we examined whether Cbl-mediated ubiquitina-The SH2 Domain of c-Cbl Binds the Phosphorylated
Form of Spry2, and the RING Finger tion of Spry2 is coupled to substrate degradation. To
increase sensitivity, HEK-293 cells were transfected withSubsequently Initiates Ubiquitination
and Proteasomal Degradation very low amounts of vectors encoding wild-type or
Y55F-Spry2, along with increasing amounts of a c-CblSince we have demonstrated that binding of c-Cbl to
Spry2 depends on tyrosine phosphorylation (Figures 2A plasmid. Under these conditions, overexpression of
c-Cbl induced significant reduction in the levels of wild-and 2E), we predicted that the SH2 domain of c-Cbl
mediates Spry2 association. To address this prediction, type Spry2, but not of the Y55F mutant (Figure 3E).
Furthermore, coexpression of the RING-defective 70Z-we used two Cbl mutants, an SH2-defective mutant
(G306E), which is unable to bind phosphorylated sub- Cbl mutant stabilized rather than destabilized Spry2.
Two lines of evidence implicate the proteasome in Cbl-strates [23], and a truncated c-Cbl mutant, which con-
tains only the SH2 domain (SH2Cbl). Upon EGF stimula- mediated degradation of Spry2. First, considering the
number of potential ubiquitination sites of Spry2 (17tion of transfected cells, we noted that wild-type c-Cbl,
as well as SH2Cbl, associated with Spry2, but the G306E lysine residues) and its pattern of poly-ubiquitination
(20 ubiquitin residues per molecule), we infer thatmutant displayed only minimal association (Figure 3A).
Moreover, although all three forms of c-Cbl were ex- branched ubiquitin chains, an effective recognition sig-
nal for the proteasome, are added to Spry2. Second, thepressed at comparable levels, much greater amounts
of Spry2 were associated with SH2Cbl, and the coimmu- proteasomal inhibitor MG132 partially inhibited c-Cbl-
mediated, EGF-induced degradation of Spry2, a phe-noprecpitated protein displayed strikingly high tyrosine
phosphorylation. According to one possible interpreta- nomenon best reflected by the level of phospho-Spry2
(Figure 3F). In conclusion, c-Cbl binds phosphorylatedtion, association of c-Cbl with Spry2 is mediated by the
SH2 domain, but complex formation is coupled to rapid Spry2 through its SH2 domain, and the flanking RING
domain initiates poly-ubiquitination and proteasomalubiquitination and degradation of the bound phosphory-
lated form of Spry2. Hence, the phosphorylated form of degradation of Spry2.
Spry2 is stabilized once it forms a complex with the
ubiquitination-defective form of c-Cbl, namely, SH2Cbl. Spry2 Inhibits c-Cbl-Mediated Ubiquitination
and Downregulation of EGFR by PreventingConsistent with this model, two RING finger mutants,
namely, 70Z-Cbl [24] and C381A-Cbl [25], retained bind- Formation of an EGFR-Cbl Complex
c-Cbl-mediated ubiquitination of EGFR promotes theing to Spry2. Additionally, both mutants associated with
significantly more phospho-Spry2, and both failed to rapid removal of activated receptors from the cell sur-
face [3, 4, 25], and Spry2 can partially inhibit this processreduce tyrosine phosphorylation of Spry2 (Figure 3B).
Based on these results, we used a Flag-tagged ubiqui- [17, 19]. Since tyrosine 55 of Spry2 is essential for c-Cbl
binding (Figure 2), we investigated its effect on receptortin to test the prediction that c-Cbl-induced ubiquitina-
(E) The indicated GST-Spry2 proteins (200 ng each; see upper part of [D]) were subjected to phosphorylation in vitro as in [D], except that
nonradioactive ATP was used, and incubation was performed in the absence or presence of AG1478 (10 M). Subsequently, the GST-fusion
proteins were used to pull down c-Cbl from overexpressing HEK-293 cells, and the associated c-Cbl protein was detected by immunoblotting.
(F) CHO cells coexpressing the indicated HA-Spry2 proteins, Myc-Cbl, and EGFR were incubated for 10 min at 37C without or with EGF (100
ng/ml), fixed, permeabilized, and incubated with anti-HA and anti-Cbl antibodies. Thereafter, cells were incubated with Cy2- and Cy3-
congugated secondary antibodies. The right column presents an overlay of Cbl fluorescence (red) and Spry2 fluorescence (green), generating
a yellow color in the areas of colocalization.
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Figure 3. The SH2 Domain of c-Cbl Binds Spry2, whereas the RING Domain Mediates Spry2 Ubiquitination and Degradation
(A) HEK-293 cells coexpressing EGFR, the indicated Myc-Cbl proteins, and HA-Spry2 (wild-type) were incubated for 10 min at 37C with EGF
(100 ng/ml), and cell extracts were analyzed as indicated. Note the weak cross-reactivity of anti-Myc antibodies with Spry2.
(B) HEK-293 cells coexpressing EGFR, the indicated HA-Cbl proteins, and HA-Spry2 were treated with EGF and were analyzed as in [A].
(C) CHO cells coexpressing EGFR and Flag-ubiquitin, along with Myc-Cbl and the indicated HA-Spry2 proteins, were incubated without or
with EGF for 10 min. Subsequently, cell extracts were analyzed with the indicated antibodies. The location of poly-ubiquitinated Spry2 is
marked.
(D) An in vitro ubiquitination reaction of the indicated GST-Spry2 proteins was performed in the presence of EGFR immunoprecipitates, GST-
Cbl, and 125I-labeled ubiquitin. Following an hour of incubation at 30C, soluble GST-Spry2 proteins were pulled down (PD) on glutathione
beads, and Spry2 ubiquitination was detected by autoradiography.
(E) HEK-293 cells were transfected with an EGFR expression vector, along with plasmids encoding the indicated HA-Spry2 proteins (0.2 g
per transfection) and HA-Cbl (either wild-type or 70Z) at the indicated quantities (in micrograms of DNA per transfection), or a control empty
vector. A total of 48 hr after transfection, the cells were incubated for 10 min at 37C without or with EGF (100 ng/ml). Subsequently, whole-
cell extracts were analyzed.
(F) CHO cells coexpressing HA-Spry2, EGFR, and Myc-Cbl were incubated without or with MG132 (20 M) for 4 hr at 37C. Subsequently,
cells were stimulated for 2 hr with EGF or were left untreated, and cell extracts were analyzed as indicated.
ubiquitination. The ubiquitination activity of the endoge- ectopic Spry2 inhibited this process (Figure 4A). Like-
wise, Spry2 inhibited c-Cbl-dependent ubiquitination ofnous c-Cbl was below our sensitivity limit. However,
when overexpressed in CHO cells, c-Cbl enhanced EGF- EGFR in a cell-free system (Figure 4B) and decelerated
the rate of EGFR removal from the cell surface (“down-induced ubiquitination and degradation of EGFR, and
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Figure 4. Spry2 Inhibits c-Cbl-Mediated Ubi-
quitination and Downregulation of EGFR by
Preventing Formation of an EGFR-Cbl
Complex
(A) CHO cells coexpressing EGFR and Flag-
ubiquitin, along with Myc-Cbl or HA-Spry2,
were incubated for 10 min at 37C without or
with EGF (100 ng/ml), and cell extracts were
analyzed with the indicated antibodies.
(B) An in vitro ubiquitination reaction of EGFR
was performed in the presence of the indi-
cated GST fusion proteins and 125I-labeled
ubiquitin. Receptor ubiquitination was de-
tected by autoradiography followed by immu-
noblotting with anti-EGFR antibodies.
(C) CHO cells coexpressing EGFR, and a
Flag-tagged ubiquitin were transfected with
HA-Cbl or a control empty vector (open circles).
Cbl-transfected cells were cotransfected
with HA-Spry2 (closed squares), Y55F-Spry2
(closed circles), or a control empty vector
(open squares). Thereafter, cells were incu-
bated at 37C with EGF (100 ng/ml) for the
indicated periods of time, and surface EGFR
was determined by the binding of 125I-EGF.
The results are presented as the mean  SD
of triplicates. This experiment was repeated
three times.
(D) HEK-293 cells coexpressing EGFR, Myc-
Cbl, and the indicated HA-Spry2 proteins
were incubated for 5 min at 37C without or
with EGF (100 ng/ml). Subsequently, cell ly-
sates were analyzed either directly or after
immunoprecipitation.
regulation,” Figure 4C). By contrast, the Y55F mutant of receptor endocytosis (Figures 4A–4C). In conclusion,
tyrosine 55 of Spry2 is essential for the inhibitory activitySpry2 inhibited neither EGFR ubiquitination (tested both
in living cells and in a cell-free system) nor ligand-induced of Spry2 upon Cbl-induced downregulation of EGFR.
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Next, we tested the prediction that Spry2 competes Sprouty, Kekkon, and Argos (reviewed in [2]). However,
unlike the Cbl pathway, which is present in worms, thewith EGFR for c-Cbl binding. To this end, we tested the
effect of Spry2 on EGFR-Cbl interactions in living HEK- other three pathways do not exist in C. elegans, sug-
gesting that they were added as secondary regulators293 cells. Following a brief stimulation with EGF, c-Cbl
underwent coimmunoprecipitation with EGFR, but ec- that fine-tune RTK function. Consistent with this notion,
our biochemical studies identified an interlinked dualtopic expression of Spry2 inhibited complex formation
(Figure 4D). Likewise, Spry2 inhibited immunoprecipita- feedback loop that combines c-Cbl and Spry2 (Figure
5C). A previously unidentified stimulus-dependent phos-tion of EGFR together with a short version of c-Cbl,
which contains only the SH2 domain (CblSH2; data not phorylation of Spry2, on an evolutionary conserved tyro-
sine residue (tyrosine 55; Figure 1), plays a key role inshown). Unlike wild-type Spry2, the Y55F mutant could
not affect binding of EGFR to the full-length form of c-Cbl these interactions. Once phosphorylated, this residue
acts as the core of an inducible docking site for the SH2(Figures 4D). Hence, it seems plausible that tyrosine-
phosphorylated Spry2 displaces c-Cbl from the phos- domain of c-Cbl (Figure 2), and, subsequently, it enables
the flanking RING finger of c-Cbl to covalently link ubi-phorylated form of EGFR, thereby reducing receptor
ubiquitination, endocytosis, and degradation. quitin molecules to Spry2 (Figure 3). Similar to trans-
phosphorylation of Spry2, a c-Cbl docking site is estab-
lished upon autophosphorylation of RTKs (e.g., tyrosineSpry2 Inhibits Signaling Attenuation by c-Cbl
One predicted outcome of the proposed competition 1045 of EGFR; [3]), and it consequently enables receptor
ubiquitination. Our results imply that these two analo-between Spry2 and EGFR for c-Cbl binding is enhance-
ment and prolongation of signals emanating from li- gous processes occur concurrently, most likely at the
plasma membrane and in endosomes (Figures 1E andgand-activated EGFRs. This prediction was tested by
using two readouts of EGFR signaling: transcriptional 2F), and that they are mutually competitive (Figure 4D).
As a result, Spry2 regulates ubiquitination and subse-activation of the c-fos promoter, a target shared by sev-
eral RTKs, including EGFR (reviewed in [26]), and the quent degradation of EGFR (Figure 4), and EGFR targets
Spry2 to proteasomal degradation (Figures 3E and 3F).kinetics of MAPK activation by EGF. As has been pre-
viously reported [25], c-Cbl inhibited EGF-induced c-fos The uncovered interplay between c-Cbl and Spry2 fine-
tunes downstream signaling (Figures 5A and 5B), whichtranscription when tested in CHO cells (Figure 5A).
Whereas wild-type Spry2 abrogated c-Cbl-mediated at- explains the role of these adaptor molecules in balanc-
ing between activation and repression of RTKs.tenuation, Y55F-Spry2 was ineffective, probably be-
cause it cannot bind to c-Cbl. Notably, Spry2, but not An interesting outcome of the coupling between phos-
phorylation and ubiquitination of Spry2 and EGFR is aY55F-Spry2, enhanced the c-fos signal even in the ab-
sence of ectopic c-Cbl (Figure 5A); this finding suggests predicted oscillation of the Spry2 level. Studies in in-
sects (reviewed in [2]) and in mammalian cells [15] re-that Spry2 targets the endogenous c-Cbl. Hence, we
examined MAPK activation in the absence of an ectopic vealed that Sprouty proteins, along with other regulators
like Kekkon and Argos, are transcriptionally induced uponc-Cbl. By using antibodies specific to the active form
of MAPK/Erk and quantification of the signal, we con- activation of RTKs. Hence, transcription from the spry2
gene is expected to follow the rapid, ligand-induced deg-cluded that EGF-induced transient activation of MAPK
was slightly prolonged in Spry2-expressing cells, radation of Spry2. Interestingly, a similar compensatory
loop enables EGF to upregulate transcription from thewhereas the Y55F mutant accelerated MAPK attenua-
tion (Figure 5B). This result is consistent with the re- egfr gene [27]. Thus, the protein degradation-based
feedback loops that regulate Sprouty and RTKs are mir-ported effect of wild-type Spry2 on MAPK activation in
HeLa cells [19]. In conclusion, the phosphorylated forms rored at the gene transcriptional level, and this bimodal
circuit ensures receptor homeostasis. Consistent withof Spry2 and EGFR compete for c-Cbl binding. Conse-
quently, Spry2 can decrease Cbl-EGFR interactions, the critical role of tyrosine 55 of Spry2 in regulating
EGFR signaling, a screen of Spry2 and Spry4 mutantsthereby inhibiting receptor desensitization processes.
identified the respective Y55F and Y53F point mutants
as dominant-negative proteins capable of potentiatingDiscussion
MAPK activation by FGF [15]. Likewise, deletion of resi-
dues 11–53 of Spry2 abolished c-Cbl binding [17], prob-Genetic screens performed in invertebrates have identi-
fied several negative regulators of RTKs, including Cbl, ably because it impairs the amino-terminal part of the
Figure 5. Spry2 Inhibits Attenuation of EGF Signaling
(A) CHO cells coexpressing a fos-luciferase reporter gene, EGFR, HA-Cbl, and the indicated forms of HA-Spry2 were treated without or with
EGF (20 ng/ml) for 12 hr. The relative luminescence signal was determined and was presented as the mean  SD of triplicates.
(B) CHO cells coexpressing the indicated HA-Spry2 proteins and EGFR were stimulated with EGF (100 ng/ml) for the indicated time intervals
at 37C. Whole-cell extracts were analyzed with the indicated antibodies, including an antibody specific to active MAPK. The resulting Western
blots (inset) and quantification of MAPK activity are shown.
(C) Model of Spry2, c-Cbl, and EGFR interactions. Ligand binding is followed by autophosphorylation of EGFR at tyrosine 1045, as well as at
other sites, and transphosphorylation of tyrosine 55 of Spry2. Each phosphotyrosine recruits the SH2 domain of c-Cbl. Subsequently, an E2
molecule associated with the RING finger (RF) of c-Cbl conjugates ubiquitin molecules (Ub) to the c-Cbl-bound substrate, either EGFR or
Spry2. Ubiquitinated EGFR is sorted for endocytosis and degradation in lysosomes, whereas modified Spry2 is degraded by proteasomes.
Due to mutual competition for c-Cbl, Spry2 can inhibit ubiquitination and subsequent degradation of EGFR. In addition, EGF activates a
transcriptionally regulated loop that replenishes the cellular pool of Spry2. TK, tyrosine kinase domain; CRD, cysteine-rich domain.
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Cells were assayed 48 hr after transfection. Cell lysis in solubilizationCbl’s docking site (Figure 1A). In contrast to our results,
buffer, immunoprecipitation, and Western blotting were carried outprevious studies identified the RING finger of c-Cbl, not
essentially as described [3].the SH2 domain, as the site of interaction with Spry2
[17, 18]. While our results do not exclude weak binding
Immunofluorescencewith the RING finger, the strong interaction between
Cells were fixed for 15 min with 3% paraformaldehyde and wereSpry2 and an SH2-only mutant of Cbl (Figure 3A) indicate
permeabilized for 10 min at 22C with PBS containing 1% albumin
that the phosphotyrosine-dependent interactions gov- and 0.2% Triton X-100. For labeling, cells were incubated for 1
ern the functional outcome in living cells. hr at room temperature with an anti-c-Cbl antibody, an anti-EGFR
antibody, or with an anti-HA monoclonal antibody. After extensiveAlong with the prospect that Sprouty proteins interfere
washing in PBS, cells were incubated for an additional hour with awith signaling events at a point upstream to that pre-
Cy2-conjugated donkey anti-mouse and a Cy3-conjugated donkeydicted by genetic [6, 7] and biochemical [13, 16] analy-
anti-rabbit antibody. Subsequently, coverslips were mounted inses, our results imply that Sprouty acts as a positive
mowiol (Calbiochem). Confocal microscopy was performed with a
rather than a negative regulator of EGF signaling, in Zeiss 510 microscope.
agreement with other reports [17–19]. It is reasonable
to assume that autophosphorylation of EGFR and sub- Radiolabeling of EGF and Receptor Downregulation Assay
sequent recruitment of c-Cbl precede the indirect trans- Human recombinant EGF was radiolabeled in an Iodogen-coated
phosphorylation of Spry2 (Figure 5C). Thus, delayed ac- tube. Transfected cells were split into a 24-well dish 1 day after
transfection. A total of 24 hr later, cells were washed with ice-coldtivation of the Spry-mediated loop is expected to occur
binding buffer, incubated at 37C for various time periods in bindingafter c-Cbl initiates receptor ubiquitination and endocy-
buffer containing EGF (100 ng/ml), and then rinsed in cold bindingtosis. In the next step, Spry2 itself is inactivated, by
buffer. Surface-bound EGF was removed by using a low pH acetic
means of ubiquitination and degradation, which enables acid solution. The number of ligand binding sites on the cell surface
a new cycle of receptor activation/inactivation. At the was then determined by incubating the cells at 4C with binding
gene expression level, EGF-induced synthesis of Spry2 buffer containing 125I-EGF (8 ng/ml) for 90 min. Nonspecific binding
was determined in the presence of a 100-fold excess of unlabeledis expected to replenish the cellular pool of active Spry2
ligand.molecules. This highly regulated sequence of events
predicts staggering waves of active RTKs and Sprouty
In Vitro Ubiquitination Assayproteins in growth factor-stimulated tissues. In the con-
EGF receptors were immunoprecipitated from cleared extracts oftext of a signaling network, such as ErbB [1], temporal
A431 cells. Following isolation, agarose beads were extensivelyregulation of the levels of RTKs and Sprouty proteins
washed with HNTG buffer, followed by an additional wash with
would enable repeated stimulation by growth factors, ubiquitin wash buffer (5 mM MgCl2, 40 nM Tris-HCl [pH 7.5]). Agarose
resist perturbations, and diversify the output by balanc- beads were then resuspended in buffer containing 5 mM MgCl2, 40
ing receptor desensitization and resensitization. mM Tris-HCl (pH 7.5), 2 mM dithiotreitol, 0.2 mM ATP, and 125I-
Ubiquitin (0.5 g per reaction). Purified E1 (160 ng), E2 (UBC-H5C;
Experimental Procedures 5 l crude bacterial extract), and GST-Cbl and GST-Spry2 fusion
proteins (100 ng each) were added, and the mixtures were incubated
Materials for 1 hr at 30C. The beads were then extensively washed, and EGFR
Unless otherwise indicated, materials were purchased from Sigma. was eluted with gel sample buffer.
Na125I was purchased from Amersham Pharmacia Biotech. IODO-
GEN was purchased from Pierce. A mutagenesis kit was purchased
c-fos Transcription Assayfrom Stratagene. Anti-hemagglutinin (HA) rat monoclonal antibody
Transfection of the indicated vectors was performed in triplicate3F10, used for immunoprecipitation and Western blotting, and anti-
with a reporter pFos.lcf plasmid (1 g), containing a human c-fosHA monoclonal mouse antibody, used for immunofluorescence
promoter (nucleotides 711 to 45) and the luciferase gene [28]. A(12CA5), were purchased from Roche Molecular Biochemicals. For
total of 24 hr later, cells were treated with EGF (20 ng/ml) or leftimmunoblot analysis of EGFR, we used a rabbit antiserum from
untreated for 12 hr. The luciferase reporter assay was performedSanta Cruz Biotechnology. A monoclonal mouse anti-phosphotyro-
by using a luciferase assay system with reporter lysis buffer (Pro-sine antibody was purchased from Santa Cruz Biotechnology. Goat
mega). The results were normalized to protein concentrations.anti-rat peroxidase-conjugated IgG was purchased from Jackson
ImmunoResearch. Peroxidase-conjugated protein A was purchased
from ICN. Construction of Expression Vectors
HA-tagged pCGN/Spry2 [19] and pGEX/GST-Spry2 [17] have been
Buffers described. The Spry2 point mutants, Myc-Cbl-G306E, as well as
The following buffers were used: binding buffer: Dulbecco’s modi- plasmids pCEFL-SH2Cbl (Proline 357 to stop) and pCEFL/Myc-Cbl
fied Eagle’s (DME) medium supplemented with 0.5% bovine serum were generated by site-directed mutagenesis. pCEFL/Myc-Cbl was
albumin and 20 mM HEPES (pH 7.5); acetic acid wash (for downregu- obtained from Dr. S. Lipkowitz (National Institutes of Health,
lation assays): 0.15 M NaCl and 0.15 M acetic acid; HNTG buffer: Bethesda). GST-Cbl has been previously described [3].
20 mM HEPES (pH 7.5), 150 mM NaCl, 0.1% Triton X-100, and 10%
glycerol; TBST buffer: 0.02 M Tris-Hcl (pH 7.5), 0.15 M NaCl, and
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